Mablink Bioscience to be acquired by Lilly

Mablink Bioscience, a pre-clinical company pioneering the development of next-generation antibody-drug conjugates via its PSARLink^TM proprietary platform, announced an agreement to be acquired by Eli Lilly and Company. The transaction is subject to approval from the French Ministry of the Economy.

Lenz & Staehelin advises Lilly in this transaction. The team includes Tino Gaberthüel (partner, M&A), Xavier Grivel (associate, M&A) and Martin Aebi (counsel, IP/litigation).